| Literature DB >> 33628065 |
Bekalu Amare Tesfaye1, Abera Hadgu Berhe1, Dawit Zewdu Wondafrash1, Derbew Fikadu Berhe1.
Abstract
BACKGROUND: Globally, cardiovascular diseases (CVDs) are becoming the major cause of death. Urtica simensis is one of endogenous plant which treats a wide range of disease conditions including heart diseases. However, there is limited information on safety and efficacy of the plant.Entities:
Keywords: Urtica simensis; cardiac biomarkers crude extract; cardioprotective; cyclophosphamide; solvent fractions
Year: 2021 PMID: 33628065 PMCID: PMC7897978 DOI: 10.2147/JEP.S270038
Source DB: PubMed Journal: J Exp Pharmacol ISSN: 1179-1454
Percentage Yield and Physical Properties of Crude Extract and Solvent Fractions of Urtica simensis
| Fractions | Colour | Actual Yield (g) | % Yield (w/w) |
|---|---|---|---|
| Aqueous | Light brown | 64 | 58.19 |
| Hexane | Black | 45.5 | 41.36 |
| Ethyl acetate | Dark brown | 0.5 | 0.45 |
Figure 1DPPH scavenging activity of ascorbic acid and Urtica simensis crude extract and solvent fractions % RSA-percentage radical scavenging activity, IC50-50% inhibition concentration.
DPPH Scavenging Activity of Crude Extract and Solvent Fraction of Urtica simensis
| Radical Scavenging Activity (%) | ||||
|---|---|---|---|---|
| Concentration (µg/mL) | Ascorbic Acid (Reference) | Crude Extracts | Aqueous Fractions | Hexane Fractions |
| 12.5 | 42.9 | 31.98 | 14.55 | 10.29 |
| 25 | 47.5 | 42.65 | 20.04 | 18.50 |
| 50 | 58.70 | 53.05 | 31.34 | 29.32 |
| 100 | 74.70 | 61.40 | 50.96 | 30.50 |
| 200 | 86.00 | 76.07 | 60.67 | 39.76 |
| IC50 (µg/µL) | 27.51 | 63.27 | 136.38 | 258.70 |
Abbreviation: IC50, 50% inhibitory concentration.
The Influence of Plant Extracts on Body Weight
| Body Weight | |||
|---|---|---|---|
| Experimental Groups | Initial Weight | Final Weight | Weight Gain (+) or Loss (−) |
| Normal control (2% tween 80%) | 377.00±8.05 | 385.67±7.47 | 8.67±4.22 |
| Negative control CP(200mg/kg i.p) | 381.50±5.75 | 363.33±4.68 | −18.17±3.05a** |
| Positive control (EN10mg/kg/Po) | 350.50±6.74 | 343.67±7.37 | −2.50±9.25 |
| CE(100mg/kg)+CP(200mg/kg) | 372.67±9.38 | 358.17±9.38 | −14.5±3.87a* |
| CE(200mg/kg)+CP(200mg/kg) | 355.50±9.01 | 341.33±7.64 | −14.17±2.98a* |
| CE(400mg/kg)+CP(200mg/kg) | 356.83±6.16 | 355.83±6.24 | −1.00±3.44 |
| AF(200mg/kg)+ CP(200mg/kg) | 360.50±9.25 | 346.00±8.02 | −14.55±2.06a* |
| AF(400mg/kg)+ CP(200mg/kg) | 365.33±7.32 | 351.00±8.58 | −14.17±2.57a* |
| HF(200mg/kg)+ CP(200mg/kg) | 372.00±8.10 | 357.00±7.14 | −15.00±2.65a* |
| HF(400mg/kg)+ CP(200mg/kg) | 384.33±0.80 | 370.00±5.11 | −14.33±4.54a* |
Notes: Mean ±SEM (n= 6); analysis was performed using one-way ANOVA followed by Tukey post hoc test; aCompared with normal control: *p<0.05, **p<0.01.
Abbreviations: AF, aqueous fraction; CE, crude extract; CP, cyclophosphamide; EN, enalapril; HF, hexane fraction; SEM, standard error of mean; Wt., weight.
The Effect of Crude Urtica simensis and Solvent Fractions on Heart Weight to Body Weight Ratio
| Heart Weight to Body Weight Ratio | |||
|---|---|---|---|
| Experimental Groups | Heart Wt. | Body Wt. | Heart Wt./Body Wt. (×10−4) |
| Normal control (2% tween 80%) | 1.18±0.02 | 385.67±7.47 | 30.70±0.60 |
| Negative control CP(200mg/kg i.p) | 1.49±0.04 | 363.33±4.68 | 41.00±0.80a*** |
| Positive control (EN 10mg/kg/Po) | 1.08±0.04 | 343.67±7.37 | 31.30±0.90b*** |
| CE(100mg/kg)+CP(200mg/kg) | 1.16±0.02 | 358.17±9.38 | 32.70±1.10b*** |
| CE(200mg/kg)+CP(200mg/kg) | 1.09±0.03 | 341.33±7.64 | 31.80±0.50b*** |
| CE(400mg/kg)+CP(200mg/kg) | 1.12±0.02 | 355.83±6.24 | 31.50±0.40b*** |
| AF(200mg/kg)+ CP(200mg/kg) | 1.14±0.02 | 346.00±8.02 | 32.80±0.30b*** |
| AF(400mg/kg)+ CP(200mg/kg) | 1.14±0.07 | 351.00±8.58 | 32.30±1.80b*** |
| HF(200mg/kg)+ CP(200mg/kg) | 1.18±0.04 | 357.00±7.14 | 32.80±0.90b*** |
| HF(400mg/kg)+ CP(200mg/kg) | 1.21±0.05 | 370.00±5.11 | 32.50±1.20b*** |
Notes: Mean ±SEM (n= 6); analysis was performed using one-way ANOVA followed by Tukey post hoc test; aCompared with normal control; bCompared with negative control (CP); ***p<0.001.
Abbreviations: AF, aqueous fraction; CE, crude extract; CP, cyclophosphamide; EN, enalapril; HF, hexane fraction; Wt., weight.
Effect of Crude Extract and Solvent Fractions of Urtica simensis on Cardiac Biomarkers
| Experimental Groups | Troponin I | ALT | AST |
|---|---|---|---|
| Normal control (2% tween 80%) | 0.11±0.01 | 56.33±14.34 | 192.83±22.85 |
| Negative control CP(200mg/kg i.p) | 0.37±0.03a** | 253.33±7.41a*** | 298.83±22.30a** |
| Positive control (EN 10mg/kg/Po) | 0.12±0.01b** | 62.83±6.66b*** | 185.00±10.09b** |
| CE(100mg/kg)+CP(200mg/kg) | 0.22±0.04 | 72.00±8.74b*** | 222.83±19.80 |
| CE(200mg/kg)+CP(200mg/kg) | 0.17±0.04b* | 66.00±10.17b*** | 216.00±15.37 |
| CE(400mg/kg)+CP(200mg/kg) | 0.15±0.03b** | 64.67±3.04b*** | 188.67±12.95b** |
| AF(200mg/kg)+ CP(200mg/kg) | 0.18±0.02b* | 85.67±26.94b*** | 201.00±17.32b* |
| AF(400mg/kg)+ CP(200mg/kg) | 0.15±0.03b* | 84.00±12.38b*** | 196.50±10.54b* |
| HF(200mg/kg)+ CP(200mg/kg) | 0.22±0.05 | 129.00±20.98a*b***c* | 248.50±19.17 |
| HF(400mg/kg)+ CP(200mg/kg) | 0.22±0.06 | 127.33±8.77a*b***c* | 249.17±28.83 |
Notes: Mean ±SEM (n= 3 for troponin I: n=6 for AST and ALT); analysis was performed using one way ANOVA followed by Tukey post hoc test; aCompared with normal control; bCompared with negative control (CP); cCompared with positive control; *p<0.05; **p<0.01; ***p<0.001.
Abbreviations: AF, aqueous fraction; ALT, alanine transaminase; AST, aspartate amino transferase; CE, crude extract; CP, cyclophosphamide; EN, enalapril; HF, hexane fraction; Wt., weight.
Effect of Crude Extract and Solvent Fractions of Urtica simensis on Lipid Profiles
| Experimental Groups | Triglycerides | Total Cholesterol |
|---|---|---|
| Normal control (2% tween 80%) | 62.00±6.13 | 44.67±6.43 |
| Negative control CP(200mg/kg i.p) | 119.00±10.98a*** | 153.83±26.36a** |
| Positive control (EN10mg/kg/Po) | 63.17±2.07b*** | 66.17±6.67b* |
| CE(100mg/kg)+CP(200mg/kg) | 69.33±10.73b** | 118.83±27.64 |
| CE(200mg/kg)+CP(200mg/kg) | 64.17±9.29b*** | 59.50±14.12b* |
| CE(400mg/kg)+CP(200mg/kg) | 56.67±2.93b*** | 53.33±14.83b** |
| Aqueous(200mg/kg)+ CP(200mg/kg) | 74.17±10.55b*** | 70.33±8.88b* |
| Aqueous(400mg/kg)+ CP(200mg/kg) | 74.00±6.35b*** | 55.67±14.06b** |
| Hexane(200mg/kg)+ CP(200mg/kg) | 76.50±8.04b* | 82.00±14.86 |
| Hexane(400mg/kg)+ CP(200mg/kg) | 77.17±12.20b* | 79.83±24.21 |
Notes: Mean ±SEM (n= 6); analysis was performed using one way ANOVA followed by Tukey post hoc test; aCompared with normal control; bCompared with negative control (CP);*p<0.05; **p<0.01; ***p<0.001.
Abbreviations: AF, aqueous fraction; CE, crude extract; CP, cyclophosphamide; EN, enalapril; HF, hexane fraction; Wt., weight.
Figure 2Histopathological changes of cardiac tissue of control and experimental rats.